Prognostic Significance of Immunoreactive Neutrophil Elastase in Human Breast Cancer: Long-Term Follow-Up Results in 313 Patients  by Akizuki, Miwa et al.
Prognostic Significance of Immunoreactive Neutrophil Elastase
in Human Breast Cancer: Long-Term Follow-Up Results
in 313 Patients1
Miwa Akizuki*, Takashi Fukutomi*, Miyuki Takasugi*, Satoshi Takahashi y, Takashi Sato z, Michiko Harao§,
Takao Mizumoto§ and Jun-ichi Yamashita y
*Department of Breast and Endocrine Surgery, Aichi Medical University, Nagakute 21, Aichi 480-1195, Japan;
yDepartment of Breast Oncology, Okazaki City Medical Association Public Health Center, Tatsumi-Nishi 1-9-1,
Okazaki 444-0875, Japan; zDepartment of Otolaryngology, Aichi-Gakuin University, Suemori-dori 2-11, Chikusa-ku,
Aichi 464-8651, Japan; §Department of Digestive Surgery, Kumamoto University Medical School, Honjo 1-1-1,
Kumamoto 860-8556, Japan
Abstract
OBJECTIVE: We have measured the concentration of
immunoreactive neutrophil elastase (ir-NE) in the tumor
extracts of 313 primary human breast cancers. Suffi-
cient time has elapsed, and we are now ready to analyze
its prognostic value in human breast cancer.METHODS:
ir-NE concentration in tumor extracts was determined
with an enzyme-linked immunosorbent assay that
enables a rapid measurement of both free-form ir-NE
and theA1-protease inhibitor–complexed formof ir-NE.
We analyzed the prognostic value of this enzyme in
human breast cancer in univariate and multivariate
analyses. RESULTS: Patients with breast cancer tissue
containing a high concentration of ir-NE had poor
survival compared to those with a low concentration
of ir-NE at the cutoff point of 9.0 Mg/100 mg protein
(P = .0012), which had been previously determined in
another group of 49 patients. Multivariate stepwise
analysis selected lymph node status (P = .0004; relative
risk = 1.46) and ir-NE concentration (P = .0013; relative
risk = 1.43) as independent prognostic factors for re-
currence. CONCLUSIONS: Tumor ir-NE concentration
is an independent prognostic factor in patients with
breast cancer who undergo curative surgery. This
enzyme may play an active role in tumor progression
that leads to metastasis in human breast cancer.
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Introduction
During invasion and metastasis formation, tumor cells con-
front a variety of natural tissue barriers in vivo, such as
basement membranes and surrounding tissue stromal
matrices composed of elastins, collagens, and proteo-
glycans. It is thus necessary for tumor cells to elaborate a
battery of extracellular matrix (ECM)–degradative enzymes
to achieve metastatic invasion. Many different types of ECM-
degradative enzymes have been implicated in the invasive
growth and metastasis of cancer cells [1–3].
The production of tumor cell proteases, including collage-
nase [4,5], plasminogen activator [6,7], and cathepsin B [8],
has been implicated in tumor cell invasion into adjacent tis-
sues and metastasis. Another proteolytic enzyme thought to be
involved in this process is elastase, which is the only protease
that is able to degrade insoluble elastin—a structural compo-
nent of elastic tissues such as blood vessel, skin, lung, and
breast tissues.
There are three well-characterized mammalian elastases.
The best characterized is porcine pancreatic elastase I, first
described by Balo and Banga [9], which is a serine protease
secreted in zymogen form by pancreatic acinar cells. The
second class of mammalian elastase is neutrophil elastase
(NE), the neutral protease found in granules of human poly-
morphonuclear leukocytes [10,11]. The third mammalian elas-
tase is a metalloprotease, which is secreted by inflammatory
macrophages [12]. Of these elastases, NE exhibits the most
proteolytic activity under physiological conditions.
The presence of elastinolytic activities in human breast
cancer tissue has been demonstrated by Hornebeck et al.
[13]; however, in their study, it was not determined whether
the activity could be attributed specifically to breast cancer
cells. Thereafter, several investigators have described elasti-
nolytic enzyme production by human and rodent mammary
tumor cells [14–16], although these enzymes have not been
isolated or characterized.
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In this connection, we previously have reported that NE is
produced by human breast cancer cell lines, using a highly
specific and sensitive enzyme immunoassay [17]. In addition,
we conducted a prognostic study of 313 patients with breast
cancer who underwent curative mastectomy and have
reported a preliminary result suggesting that the concentra-
tion of immunoreactive neutrophil elastase (ir-NE) in tumor
extracts may affect prognosis in human breast cancer [18].
Sufficient time has elapsed, and we are now ready to analyze
prognosis in patients with breast cancer.
Materials and Methods
Patients
Three hundred thirteen patients with breast cancer in the
present analysis constitute 100% of our previous study popu-
lation [18]. These patients underwent curative mastectomy
with lymph node dissection at the Department of Surgery II,
Kumamoto University Hospital, between March 1982 and
April 1989. The median follow-up period for patients was
18.5 years (range, 14.0–21.1 years). The clinicopathological
characteristics of the 313 patients are summarized in Table 1.
Assay for ir-NE
Breast cancer specimens were homogenized and ex-
tracted with 50 mM Tris–HCl buffer (pH 7.4) containing
0.25% Triton X-100, as described previously [23]. The re-
sulting supernatant was assayed for ir-NE concentration as
described below.
The concentration of ir-NE in tumor extracts was de-
termined with a newly established enzyme immunoassay
kit (Mochida Pharmaceutical Co., Tokyo, Japan). This is a
sensitive assay that enables a rapid measurement of both
NE-complexed a1-protease inhibitor (a1-PI) and free-form
NE [24]. When 0.1 ml of tissue extract was used, the detec-
tion limit of ir-NE was 0.063 mg/100 mg protein. The intra-
assay and interassay coefficients of variation were 3.2% to
5.6% and 5.1% to 8.7%, respectively.
To measure the level of free-form and a1-PI–complexed
form in tissue extracts, we determined the concentration of
ir-NE in all samples in the presence and in the absence of an
excess amount (100 mg/ml) of a1-antitrypsin (Sigma, St. Louis,
MO) using the conventional Merck kit (E. Merck, Darmstadt,
Germany) according to the method of Neumann et al. [25].
Because the Merck kit detects only NE complexed with a1-PI,
the difference between these concentrations was regarded
as free-form ir-NE, and the concentration in the absence of
a1-antitrypsin was regarded as the a1-PI–complexed form
of ir-NE.
Survival Analysis
Routine postoperative follow-up consisted of clinical eval-
uations every month for the first 2 years and every 3 to
6 months thereafter. Disease recurrence was documented
by physical examination, roentgenographic and laboratory
tests, and other relevant diagnostic procedures. The major
statistical endpoint of this study was disease recurrence
(distant recurrences only) and was calculated from the day
of operation to the day of discovery of recurrence or the
last known date alive. Event time distribution was estimated
with the method of Kaplan and Meier [26]. Differences
between death distributions were tested for statistical sig-
nificance with the log-rank test [27]. For simultaneous control
of the effects of many variables on differences in death rates,
a multivariate proportional hazards regression model [28]
was used. P < .05 was considered significant.
Table 1. Relation between ir-NE Content in Tissue Extracts and Clinico-
pathological Factors of Human Breast Cancer (n = 313).
Characteristic Content
(mg/100 mg Protein)
n (%) ir-NE (Mean ± SD)
Menstrual status
Premenopause/perimenopause 179 (57) 5.24 ± 4.11
Postmenopause 134 (43) 4.32 ± 3.50
Tumor size (cm)
< 2.0 57 (18) 3.38 ± 1.13
2.0–5.0 176 (56) 4.55 ± 3.25
> 5.0 80 (26) 7.20 ± 5.12*
Lymph node status
Node-negative 178 (57) 2.54 ± 1.90
Node-positive 135 (43) 5.47 ± 4.24y
Histologic typez
Papillotubular 72 (23) 3.26 ± 3.01
Solid– tubular 117 (37) 4.66 ± 3.86
Scirrhous 111 (35) 5.11 ± 3.92
Other 13 (4) 4.28 ± 3.99
Histologic grade§
I 90 (29) 4.42 ± 3.76
II 122 (39) 4.63 ± 3.73
III 101 (32) 5.89 ± 5.01
Vessel involvement
Absent 194 (62) 4.22 ± 4.05
Present 119 (38) 4.96 ± 3.97
Estrogen receptorb
Positive 159 (51) 5.52 ± 4.03
Negative 124 (40) 4.14 ± 3.63
Unknown 30 (10) 4.68 ± 4.00
Progesterone receptorb
Positive 94 (30) 5.38 ± 4.24
Negative 178 (57) 4.29 ± 3.62
Unknown 41 (13) 4.21 ± 3.97
Type of surgery#
Halsted 75 (24) 4.51 ± 3.93
Modified 238 (76) 5.72 ± 4.10
Adjuvant therapy
Endocrine therapy 75 (24) 3.45 ± 3.19
Chemotherapy 45 (14) 4.51 ± 4.13
Both 92 (29) 3.96 ± 3.22
None 101 (32) 4.07 ± 3.18
Immunoreactive NE
< 9.0 261 (83)
z 9.0 52 (17)
*P < .002, compared with <2.0 and 2.0 to 5.0 cm.
yP < .001, compared with node-negative.
zBreast tumor was analyzed according to the classification of the Japanese
Breast Cancer Society [19]. When histologic typing was performed according
to World Health Organization classification [20], all tumors were classified as
invasive ductal carcinoma.
§Breast tumor was graded according to the criteria described by Bloom and
Richardson [21].
bEstrogen receptor and progesterone receptor were determined by a dextran-
coated charcoal method [22]. Tumors were considered hormone receptor –
positive if they contained at least 10 fmol of specific binding sites per
milligram of protein.
#During the mid-1980s, Halsted mastectomy or modified radical mastectomy
preserving the pectoral muscles was widespread in Japan, although breast
conservation surgery for breast cancer had become common in Western
countries.
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Results
Relation of ir-NE Content to Clinicopathological Factors
Table 1 shows the correlation between ir-NE content
and the characteristics of the patients in this series. When
ir-NE content was compared in terms of menstrual status,
histologic type, histologic grade, vessel involvement, es-
trogen receptor, and progesterone receptor, no significant
association was found between ir-NE content and any of
these features. However, ir-NE content was significantly
higher in tumors with a size of > 5.0 cm than in those with
< 5.0 cm (P < .002). Similarly, ir-NE content was significantly
higher in patients who were node-positive than in those who
were node-negative.
Univariate Analysis
As expected, lymph node status, tumor size, histologic
grade, vessel involvement, and adjuvant therapy were found
to have a significant effect on disease-free survival when
evaluated in a univariate analysis. When patient prognosis
was analyzed in terms of the results of ir-NE, patients with
breast cancer tissues containing a high concentration of
ir-NE had a disease-free survival time significantly shorter
than that in patients with a low content of ir-NE (P = .0012;
Figure 1 and Table 2). In this analysis, the cutoff point of
9.0 mg/100 mg protein was used because our preliminary
study of another 49 patients [17] revealed that this cutoff
point could give a statistically significant separation for risk
of relapse, according to the method of Tandon et al. [29]. This
cutoff point identified 16.6% (52 of 313) of the patients as
having high ir-NE levels in the present series.
Multivariate Analysis
To verify the independent nature of the prognostic value
of ir-NE concentration, we used multivariate analysis. Cox
regression analysis of overall survival, allowing for menstrual
status, tumor size, lymph node status, histologic type, histo-
logic grade, vessel involvement, estrogen receptor, proges-
terone receptor, type of surgery, adjuvant therapy, and ir-NE,
showed that lymph node status is the single independent
prognostic factor of disease-free survival (P = .0012; relative
risk = 1.62; Table 2). To eliminate the effect of the inclusion
of not so important variables into the model, we also per-
formed stepwise regression analysis with a 5% significance
level. Through a stepwise method, the model selected lymph
node status (P = .0004; relative risk = 1.46) and ir-NE
concentration (P = .0013; relative risk = 1.43) (Table 3).
Menstrual status, tumor size, histologic type, histologic
grade, vessel involvement, estrogen receptor, progesterone
receptor, type of surgery, and adjuvant therapy were not in-
dependent prognostic factors.
Discussion
The purpose of identifying prognostic factors in breast
cancer is to provide a sound basis for the rational manage-
ment of the disease. Reliable predictors of cancer recurrence
and death in patients with breast cancer may help to deter-
mine the selection of adjuvant chemotherapy or endocrine
therapy. Classic prognostic factors, such as age, tumor size,
Table 2. Univariate and Cox Regression Analyses as Prognostic Factors for
Relapse in Patients with Breast Cancer.
Variable Univariate
Analysis
Multivariate
Analysis
Relative
Risk
P Z SE P
Independently associated with relapse
Lymph node status (node-negative
vs node-positive)
.0012 1.68 0.54 .0001 1.62
Associated with relapse only when evaluated alone
Tumor size (< 2.0 vs 2.0–5.0
vs > 5.0 cm)
.0431 0.46 0.32 .324 1.04
Histologic grade (I vs II vs III) .0088 –0.74 0.39 .163 0.62
Vessel involvement (absent vs
present)
.0315 –0.62 0.24 .112 1.51
Adjuvant therapy (endocrine vs
chemotherapy vs both vs none)
.0048 0.53 0.33 .103 0.54
ir-NE (< 9.0 vs z 9.0) .0012 0.45 0.31 .062 1.50
Not associated with relapse
Menstrual status (premenopause/
perimenopause vs
postmenopause)
.4226 0.70 0.40 .504 1.57
Histologic type (papillotubular vs
solid – tubular vs scirrhous vs
other)
.1003 0.04 0.45 .754 0.17
Estrogen receptor (positive vs
negative vs unknown)
.7314 –1.47 0.33 .214 1.08
Progesterone receptor (positive vs
negative vs unknown)
.1571 0.79 0.38 .133 1.52
Type of surgery (Halsted vs
modified)
.9174 0.61 0.44 .417 0.81
Table 3. Final Stepwise Regression Analysis.
Variable Z SE P Relative Risk
Lymph node status 1.55 0.49 .0004 1.46
ir-NE 0.39 0.11 .0013 1.43
Figure 1. Relapse-free survival curves in 313 patients with breast cancer in
terms of ir-NE concentration in tumor extracts. The major statistical endpoint
of this study was disease recurrence (distant recurrences only). The cutoff
point between high and low enzyme levels is 9.0 g/100 mg protein. Numbers
in parentheses show the total number of patients per group.
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lymph node involvement, histologic grade, and hormone
receptor status, assist in predicting the patient’s outcome or
response to treatment, but they are not entirely dependable.
Several enzymes or biologic factors determined in the cyto-
plasm and organelles of tumor cells have been found to have
prognostic value in human breast cancer [29,30].
In the present study, we have demonstrated that the ir-NE
concentration in tumor extracts is an independent prognostic
factor that clearly identifies patients at high risk and at low
risk for the disease, indicating that this enzyme level can be
added to the list of second-generation prognostic factors
in human breast cancer [31–33]. NE is the only neutral pro-
tease that is able to degrade insoluble elastin [11,34]. NE can
also hydrolyze other ECM proteins, including type IV colla-
gens [35], fibronectins [36], and proteoglycans [37], and has
been reported to potentiate the conversion of plasminogen to
plasmin by urokinase-type plasminogen activator [38]—an
enzyme that has been postulated to play a role in cancer
spread [39]. Thus, tumor NE may play a pathologic role in
facilitating cancer cell invasion and metastasis, either di-
rectly by the dissolution of the tumor matrix or indirectly
through such a protease cascade. The results presented
here—demonstrating that free-form (active form) NE, but
not the a1-PI–complexed form (inactive form), contributes
to the prognostic value in human breast cancer—may sup-
port the above assumption.
The interactions between tumor and normal cells are
complex events that occur continuously throughout the en-
tire invasion process. A wide variability in the relative propor-
tions of tumor and host cells has been observed at the zone
of tumor invasion. Breast tumors also are heterogenous, with
varying tumor cellularities and amounts of stroma. It is
therefore possible that some of the NE proteins detected in
this study that assayed tumor cytosols were extracted from
infiltrating inflammatory cells and that this inflammatory cell
involvement correlated with poor prognosis. Normal cells,
such as neutrophils, fibroblasts, macrophages, and lympho-
cytes, all of which appear in the tumor invasion zone, may
cooperate for the destruction of the host ECM. In fact,
inflammatory cell infiltration has been reported to be asso-
ciated with poor prognosis in human breast cancer [40].
In conclusion, tumor NE, whatever the cellular origin, may
play an active role in the tumor progression that leads to
metastasis in human breast cancer. The long-term follow-up
results presented here, demonstrating that free-form NE is a
strong and independent prognostic factor in human breast
cancer, may support the above assumption.
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